Numis Securities gave Advanced Medical Solutions Group plc (LON:AMS) some tender loving care after the health group unveiled higher annual profits and dividends.
Numis upgraded AMS to 'add' from 'hold' as the surgical and wound care product maker boosted adjusted pre-tax profits 12% to £17.4mln on an 11% lift in revenue to £68.6mln in the year to December 31.
AMS also proposed a final dividend of 0.55p per share, resulting in a total dividend for the year of 0.8p, up 14.3% from 0.7p a year ago.
The company reported good sales across all its business areas on a constant currency basis, including an 8% rise in revenue for its ActivHeal product due to good demand from the UK's NHS.
Numis, which also raised its target price to 205p, described the results as strong despite modest currency headwinds.
It added: "AMS has launched a series of new products in 2015, that should sustain solid growth into 2016, and with a burgeoning cash balance the company is well-placed to accelerate growth through acquisition."
Antofagasta plc (LON:ANTO) lost its shine after Citigroup downgraded the Chilean miner to 'neutral' from 'buy'.
Citi said it continued to believe the miner was a "trough cycle survivor" and expected it to generate free cash flow consistently from 2017 onwards.
But the broker added: "The stock price is up ~40% from its January low despite ~20% correction from the peak and looks fairly valued to us." Antofagasta's shares fell 13p, or 2.5%, to 500.5p.
Cairn Energy PLC (LON:CNE) ticked up 2.3p to 193.8p as Credit Suisse upgraded the oil explorer and producer to 'neutral' from 'underperform' with a price target of 190p, up from 130p previously.
Credit Suisse said a resource upgrade by the company at its SNE field in Senegal led the broker to increase its base case resource estimate to 385 million barrels from 330 million barrels.
Barclays downgraded GYM Group PLC (LON:GYM) to 'equal weight' from 'overweight' based on its share price performance since the group's IPO among other factors.
"Given strong performance and minimal upgrades, we believe the FY16 EV/EBITDA rating of 14x fairly captures the attractive future growth prospects."